We present a case of scleroderma complicated by severe pulmonary hypertension. The use of a three-drug (bosentan, iloprost, and sildenafil) 
Introduction

Pulmonary arterial hypertension (PH) is an important cause of mortality and worsening health status in interstitial lung disease. It occurs in up to 27% of patients with scleroderma, and earlier treatment is associated with better treatment outcomes (1). Different vasodilators have been proven to be effective, but only combinations of two drugs have hitherto been tested (2-4). We describe the efficacy and safety of triple-drug vasodilator therapy in a patient with severe PH secondary to scleroderma.
Case Report
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Clinical conditions rapidly improved and at day
 (Fig. 1B) 
Discussion
PH complicating connective tissue diseases variably depends upon parenchimal and pulmonary arterial changes (5).
Relieving the hypoxemia is the mainstay of therapy, but lately PH resists this measure. At this stage, selected pulmonary vasodilators could be effective (2) . Previous experience shows that the addition of bosentan to inhaled iloprost or oral beraprost has additive effects, at least in primary PH (6) 
